Dupla Dorota, Fraczek Marcin, Krecicki Tomasz, Woźniak Zbigniew
Zakład Teleradioterapii, Dolnoślaskie Centrum Onkologii we Wrocławiu.
Otolaryngol Pol. 2009 Mar-Apr;63(2):136-40. doi: 10.1016/S0030-6657(09)70094-0.
Cyclin B1 and cyclin D1 playing the role of regulatory subunits of cyclin-dependent kinases responsible for progression of cell cycle are involved in carcinogenesis of head and neck tumors. The aim of this study is to investigate their value for predicting clinical outcome after radiotherapy of laryngeal squamous cell cancer (LSCC).
The study included 50 patients with LSCC treated between the years 1998 and 2003 with radiotherapy. Tissue samples were studied immunohistochemically for detection of cyclin B1 and cyclin D1 and their expression were correlated with clinicopathological factors, local tumor control and patient survival.
Accumulation of cyclin D1 and cyclin B1 were detected in 36% and 48% of tumors respectively. No relationship was observed between immunostaining for analyzed proteins and clinicopathologic factors. Cyclin B1 overexpression was associated with higher rate of locoregional recurrence. Five-year disease free survival rate for patients with cyclin B1 positive tumors was 73% v. 84% for cyclin B1 negative patients (p=0.005).
The expression of cyclin D1 in LSCC does not seem to have a prognostic significance. Overexpression of cyclin B1 may be an indicator of the risk of locoregional recurrence in patient receiving radiotherapy. Thus cyclin B1 detected by immunohistochemistry can be useful for predicting outcome of radiotherapy in patients with LSCC.
细胞周期蛋白B1和细胞周期蛋白D1作为细胞周期蛋白依赖性激酶的调节亚基,负责细胞周期的进展,参与头颈部肿瘤的致癌过程。本研究旨在探讨它们在预测喉鳞状细胞癌(LSCC)放疗后临床结局中的价值。
本研究纳入了1998年至2003年间接受放疗的50例LSCC患者。对组织样本进行免疫组化研究,以检测细胞周期蛋白B1和细胞周期蛋白D1,并将它们的表达与临床病理因素、局部肿瘤控制和患者生存率相关联。
分别在36%和48%的肿瘤中检测到细胞周期蛋白D1和细胞周期蛋白B1的积累。未观察到所分析蛋白质的免疫染色与临床病理因素之间的关系。细胞周期蛋白B1的过表达与更高的局部区域复发率相关。细胞周期蛋白B1阳性肿瘤患者的五年无病生存率为73%,而细胞周期蛋白B1阴性患者为84%(p = 0.005)。
细胞周期蛋白D1在LSCC中的表达似乎没有预后意义。细胞周期蛋白B1的过表达可能是接受放疗患者局部区域复发风险的一个指标。因此,通过免疫组化检测到的细胞周期蛋白B1可用于预测LSCC患者的放疗结局。